| Story Views | |
| Now: | |
| Last Hour: | |
| Last 24 Hours: | |
| Total: | |
Akari Therapeutics shares bolstered by FDA move
Emerging biotech firm Akari Therapeutics Plc (NYSE: AKTX) rose on Thursday as it told investors that the US FDA had given one of its treatments fast-track status.
Coversin is for treating paroxysmal nocturnal hemoglobinuria, or PNH – a rare and chronic blood disorder.
Fast track designation by the FDA means development can be accelerated on new drugs which show promise in treating a serious or life-threatening disease and address an unmet medical need.
Chief executive Dr Gur Roshwalbs said: “We are very proud of the continued advancement of our Coversin program for the treatment of PNH in patients with or without polymorphisms.”
“The FDA fast track designation recognizes the unmet need in patients with PNH who cannot be treated with the current standard of care due to polymorphisms.”
Shares of Akari ended the day up over 5% at $6.98.
Story by ProactiveInvestors
Source: http://www.proactiveinvestors.com/companies/news/175715/akari-therapeutics-shares-bolstered-by-fda-move-175715.html
